Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31382118 | 0.72 | SLC6A2 (0.39) | KMT2ASMN1; SMN2MAPTRAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL31382368 | 0.71 | SLC6A2 (0.38) | KMT2ASMN1; SMN2MAPTRAB9ANPC1 | |
| SCHEMBL15321889 | 0.71 | HCAR2 (0.47) | KMT2ASMN1; SMN2MEN1POLBALDH1A1 | |
| SCHEMBL16590521 | 0.71 | SLC6A2 (0.38) | KMT2ASMN1; SMN2MAPTRAB9ANPC1 | |
| SCHEMBL20320549 | 0.69 | SLC6A2 (0.40) | KMT2ASMN1; SMN2MAPTRAB9ANPC1 | |
| SCHEMBL29138452 | 0.69 | KMT2A (0.35) | KMT2ASMN1; SMN2MAPTRAB9ANPC1 | |
| SCHEMBL30048866 | 0.69 | SMN1; SMN2 (0.36) | KMT2ASMN1; SMN2MAPTRAB9ANPC1 | |
| SCHEMBL24072577 | 0.68 | TRPM8 (0.38) | KMT2ASMN1; SMN2MAPTRAB9ANPC1 | |
| SCHEMBL29066652 | 0.67 | SMN1; SMN2 (0.58) | KMT2ASMN1; SMN2MAPTRAB9ANPC1 | |
| SCHEMBL20320551 | 0.67 | SLC6A2 (0.35) | KMT2ASMN1; SMN2MAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359415-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117355531-A | Diacylglycerol kinase modulating compounds | 吉利德科学公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2022271684-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-2834238-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9296745-B2 | Diacylglycerol acyltransferase 2 inhibitors | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2015-03-26 | — | — | US | disclosed |
| EP-2834238-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | Pfizer Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013150416-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, PLAAT2 | KMT2A 770/4885SMN1; SMN2 3813/4885MAPT 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.